Dynavax Technologies Corporation
DVAXUnited States
42 filed reports · 531 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $277MFY2024 · to Dec 31, 2024+19.4% from $232M10-K | $94.9MQ3 FY2025 · to Sep 30, 2025+17.7% from $80.6M10-Q |
| Net income | $27.3MFY2024 · to Dec 31, 2024a year earlier: -$6.39M10-K | $26.9MQ3 FY2025 · to Sep 30, 2025+53.0% from $17.6M10-Q |
| Operating income | -$4.12MFY2024 · to Dec 31, 2024a year earlier: -$37M10-K | $21.3MQ3 FY2025 · to Sep 30, 2025+111% from $10.1M10-Q |
Filed reports
42 reports · Jun 2015 to Sep 2025Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 32 | 5,114 | Jun 2015 to Sep 2025 |
| Annual · 10-KSEC EDGAR | 10 | 4,492 | Dec 2015 to Dec 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 393 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 272 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 285 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 20, 2025 | 983 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 176 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 167 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 177 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 22, 2024 | 505 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 190 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 3, 2023 | 185 | Open |
| FY2023 Q1 | 10-Q | Mar 31, 2023 | May 2, 2023 | 197 | Open |
| FY2022 | 10-K | Dec 31, 2022 | Feb 23, 2023 | 501 | Open |
Financial data
531 concepts · 9,606 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial497 concepts · 9,024 facts · Dec 2011 to Sep 2025
- Cash and cash equivalents at carrying value59 · Dec 2013 to Sep 2025
- Comprehensive income net of tax59 · Dec 2013 to Sep 2025
- Investment income interest59 · Dec 2013 to Sep 2025
- Net income loss59 · Dec 2013 to Sep 2025
- Operating income loss59 · Dec 2013 to Sep 2025
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax59 · Dec 2013 to Sep 2025
- Other comprehensive income loss net of tax59 · Dec 2013 to Sep 2025
- Other nonoperating income expense59 · Dec 2013 to Sep 2025
- Research and development expense59 · Dec 2013 to Sep 2025
- Revenue59 · Dec 2013 to Sep 2025
- Accretion amortization of discounts and premiums investments57 · Dec 2013 to Sep 2025
- Depreciation and amortization57 · Dec 2013 to Sep 2025
- Increase decrease in accounts payable57 · Dec 2013 to Sep 2025
- Increase decrease in accrued liabilities and other operating liabilities57 · Dec 2013 to Sep 2025
- Increase decrease in prepaid deferred expense and other assets57 · Dec 2013 to Sep 2025
- Payments to acquire marketable securities57 · Dec 2013 to Sep 2025
- Payments to acquire property plant and equipment57 · Dec 2013 to Sep 2025
- Proceeds from sale and maturity of available for sale securities57 · Dec 2013 to Sep 2025
- Proceeds from stock plans57 · Dec 2013 to Sep 2025
- Share based compensation57 · Dec 2013 to Sep 2025
- Stockholders equity (US GAAP)56 · Dec 2013 to Sep 2025
- Common stock par or stated value per share55 · Dec 2014 to Sep 2025
- Accounts payable current54 · Dec 2014 to Sep 2025
- Accrued liabilities current54 · Dec 2014 to Sep 2025
Product24 concepts · 442 facts · Dec 2016 to Sep 2025
- Revenue333 · Dec 2016 to Sep 2025
- Cost of goods and services sold amortization17 · Dec 2017 to Sep 2021
- Cost of goods and service excluding depreciation depletion and amortization16 · Sep 2018 to Sep 2021
- Deferred revenue additions9 · Dec 2020 to Dec 2022
- Deferred revenue revenue recognized18 · Sep 2021 to Dec 2022
- Cost of goods and services sold (US GAAP)7 · Mar 2018 to Jun 2019
- Inventory write down6 · Dec 2019 to Dec 2024
- Contract with customer asset sale5 · Dec 2021 to Mar 2024
- Contract with customer asset purchase4 · Dec 2022 to Mar 2024
- Product Revenue Allowance And Reserves Credit Or Payments Made During Period4 · Mar 2018 to Mar 2021
- Product Revenue Allowance And Reserves Provision Related To Current Period Sales4 · Mar 2018 to Mar 2021
- Concentration risk percentage13 · Mar 2020 to Mar 2021
- Contract with customer asset cumulative catch up adjustment to revenue modification of contract3 · Mar 2022 to Sep 2022
- Contract with Customer, Asset, Purchase, Current3 · Dec 2023 to Mar 2025
- Contract with Customer, Asset, Purchase, Noncurrent3 · Dec 2023 to Mar 2025
- Contract with Customer, Asset, Sale, Current3 · Dec 2023 to Mar 2025
- Contract with Customer, Asset, Sale, Noncurrent3 · Dec 2023 to Mar 2025
- Contract with customer asset change in method credit loss expense reversal2 · Mar 2023 to Dec 2023
- Contract with Customer, Asset, Change in Method, Credit Loss Expense (Reversal), Current2 · Dec 2023 to Dec 2024
- Deferred Revenue Subtractions2 · Dec 2021 to Dec 2022
- Increase decrease in contract with customer asset2 · Dec 2021 to Mar 2022
- Net income loss1 · Dec 2021
- Number Of Vials In Inventory1 · Dec 2017
- Revenue From Contract With Customer Increase Decrease1 · Dec 2020
Geography3 concepts · 70 facts · Dec 2013 to Sep 2025
- Revenue58 · Dec 2019 to Sep 2025
- Percentage Of Revenue Earned10 · Dec 2013 to Dec 2020
- Business exit costs12 · Dec 2013 to Dec 2014
Segment7 concepts · 70 facts · Dec 2022 to Sep 2025
- Cost of goods and service excluding depreciation depletion and amortization10 · Dec 2022 to Sep 2025
- General and administrative expense (US GAAP)10 · Dec 2022 to Sep 2025
- Net income loss10 · Dec 2022 to Sep 2025
- Research and development expense10 · Dec 2022 to Sep 2025
- Revenue10 · Dec 2022 to Sep 2025
- Segment reporting other item amount10 · Dec 2022 to Sep 2025
- Selling and marketing expense (US GAAP)10 · Dec 2022 to Sep 2025
Segments
582 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis7 members · 439 facts
- Product133 · Dec 2017 to Sep 2025
- HEPLISAV-B®104 · Dec 2018 to Sep 2025
- CpG 1018102 · Sep 2020 to Mar 2025
- Other Revenue88 · Dec 2017 to Sep 2025
- Collaboration Revenue5 · Dec 2016 to Dec 2019
- Grant Revenue5 · Dec 2016 to Dec 2017
- Service and License Revenue2 · Dec 2016 to Dec 2017
Statement business segments1 member · 70 facts
- Reportable Segments70 · Dec 2022 to Sep 2025
Statement geographicalsrt:StatementGeographicalAxis2 members · 63 facts
- United States34 · Dec 2016 to Sep 2025
- Non-US29 · Dec 2019 to Sep 2025
Statement geographicalus-gaap:StatementGeographicalAxis2 members · 7 facts
- United States5 · Dec 2013 to Dec 2017
- Berkeley, California (the "Berkeley Lease")2 · Dec 2013 to Dec 2014
Product or serviceus-gaap:ProductOrServiceAxis2 members · 3 facts
- HEPLISAV-B®2 · Mar 2018
- HEPLISAV-B™1 · Dec 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Dynavax Technologies Corporation (DVAX) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.